Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04204005
Other study ID # 215/CE n.CE 30\17
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 13, 2017
Est. completion date December 31, 2020

Study information

Verified date December 2019
Source Probiotical S.p.A.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Here the investigators will perform a double-blinded randomized placebo-controlled clinical trial to evaluate the synergic effect of low protein diet and prebiotics in reducing the microbial inflammatory uremic toxins.


Description:

ProLowCKD is a single-centre, double-blind, placebo-controlled, randomised study. At enrolment (T0) participants were prescribed a LPD in addition to their ongoing pharmacological therapy and according to their comorbidities; after 2 months (T2) they were randomized in accordance to a 1:1 ratio to receive probiotics or placebo for other 3 months (T5) in addition to the continuation of LPD. Enrolled subjects are invited to assume two doses of probiotic/placebo for 1 month and 1 dose for 2 months. Randomization is 1:1 to receive odd- or even envelopes, according to the odd- or even registration number at enrolment. Neither the clinician nor the patient knows the content of the odd- and even envelopes. The evaluations will be performed according to the following schedule: at T0 nephrological evaluation and biochemical analysis, dietary counselling, illustration of protocol and signing of the informed consent, administration of the SF36 questionnaire, body composition evaluation by bioimpedentiometry. At T0, T2, T5: blood biochemical parameters: haemoglobin, urea, creatinine, mean urea and creatinine clearance, CKD and MDRD calculation, sodium, potassium, uric acid, calcium, phosphate, PTH, acid-base balance, CRP, albumin, PC, IS, Lp-PLA2, LPS; 24h-urine biochemical parameters: urea, creatinine, sodium, proteins; microbial stools analysis; clinical nephrological and dietitian evaluation.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date December 31, 2020
Est. primary completion date December 31, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - age 18-80 years - GFR < 20 ml/min/sqm - afferent to the outpatient clinic in the Nephrology and Dialysis Unit (Azienda Ospedaliero Universitaria Maggiore della Carità) Drop out or Exclusion Criteria: - subject refusing to sign the informed consent - administration of prolonged antibacterial therapy - dialysis initiation - death

Study Design


Intervention

Dietary Supplement:
Probiotics
Active composition: 5x109 of Bifidobacterium longum (mix DLBL), 1x 109 Lactobacillus reuteri LRE02 (DSM 23878) and maltodextrin (total 2 grams). The probiotic species employed were granted the Qualified Presumption of Safety (QPS) status by the European Food Safety Authority (EFSA) in 2007. Two envelopes per day and one envelope per day will be recommended for one and two months, respectively. Placebo composition: maltodextrin (2 grams). Two envelopes per day and one envelope per day will be recommended for one and two months, respectively.

Locations

Country Name City State
Italy Nephrology and Dialysis Unit, Azienda Ospedaliero Universitaria Maggiore della Carità Novara

Sponsors (2)

Lead Sponsor Collaborator
Probiotical S.p.A. Azienda Ospedaliero Universitaria Maggiore della Carita

Country where clinical trial is conducted

Italy, 

References & Publications (6)

Mafra D, Fouque D. Gut microbiota and inflammation in chronic kidney disease patients. Clin Kidney J. 2015 Jun;8(3):332-4. doi: 10.1093/ckj/sfv026. Epub 2015 May 6. — View Citation

Mafra D, Lobo JC, Barros AF, Koppe L, Vaziri ND, Fouque D. Role of altered intestinal microbiota in systemic inflammation and cardiovascular disease in chronic kidney disease. Future Microbiol. 2014;9(3):399-410. doi: 10.2217/fmb.13.165. Review. — View Citation

Marchesi JR, Adams DH, Fava F, Hermes GD, Hirschfield GM, Hold G, Quraishi MN, Kinross J, Smidt H, Tuohy KM, Thomas LV, Zoetendal EG, Hart A. The gut microbiota and host health: a new clinical frontier. Gut. 2016 Feb;65(2):330-9. doi: 10.1136/gutjnl-2015-309990. Epub 2015 Sep 2. Review. — View Citation

Ramezani A, Massy ZA, Meijers B, Evenepoel P, Vanholder R, Raj DS. Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target. Am J Kidney Dis. 2016 Mar;67(3):483-98. doi: 10.1053/j.ajkd.2015.09.027. Epub 2015 Nov 15. Review. — View Citation

Rossi M, Klein K, Johnson DW, Campbell KL. Pre-, pro-, and synbiotics: do they have a role in reducing uremic toxins? A systematic review and meta-analysis. Int J Nephrol. 2012;2012:673631. doi: 10.1155/2012/673631. Epub 2012 Dec 19. — View Citation

Vaziri ND. Effect of Synbiotic Therapy on Gut-Derived Uremic Toxins and the Intestinal Microbiome in Patients with CKD. Clin J Am Soc Nephrol. 2016 Feb 5;11(2):199-201. doi: 10.2215/CJN.13631215. Epub 2016 Jan 15. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline of the microbial gut populations Change from baseline of the concentration of proteolytic microbial groups (number of cells/gram of faeces);
Change from baseline of the concentration of saccharolytic microbial groups (number of cells/gram of faeces)
5 months
Primary Change from baseline of the microbial inflammatory uremic toxins Change from baseline of the serum concentration of PC (mcMOL) and IS (mcMOL), as markers of dysbiotic microbiota 5 months
Primary Change from baseline of the markers of cardiovascular diseases Change from baseline of the serum concentration of Lp-PLA2 (nmol/ml/min) 5 months
Primary Change from baseline of the markers of intestinal barrier permeability Change from baseline of the serum concentration of LPS (EU/ml) 5 months
Secondary Evaluation of the renal function Change from baseline of ?GFR (mL/min/m2 of body surface) 5 months
Secondary Measurement of the urine protein excretion Change from baseline of 24-hour protein urine excretion (mg/24 hours) 5 months
Secondary Evaluation of the anemia Change from baseline of haemoglobin (g/dL) 5 months
Secondary Evaluation of the serum acid-base equilibrium Change from baseline of bicarbonatemia (mEq/l) 5 months
Secondary Quantification of serum inflammatory markers Change from baseline of the serum concentration of C-reactive protein (CRP) (mg/dL) 5 months
Secondary Evaluation of the body composition Change from baseline of fat-free body mass (kg), fat-body mass (kg), Hand Grip strength (kg), total body water (kg) 5 months
Secondary Measurement of vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning and mental health (Quality of Life) Change from baseline of SF36 questionnaire score. The SF36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability. 5 months
See also
  Status Clinical Trial Phase
Completed NCT03246984 - VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ N/A
Completed NCT05787080 - Massage, Oxidative and Antioxidant Enzymes in Hemodialysis Patients With Restless Legs Syndrome(RLS) N/A
Completed NCT05585268 - Electronic Decision Support for Deprescribing in Patients on Hemodialysis N/A
Completed NCT02332811 - An Open Label, Dose Titration Study of Sevelamer Carbonate Tablets & Powder in Hyperphosphatemic CKD Patients Phase 3
Withdrawn NCT03093740 - Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant Phase 4
Recruiting NCT04908345 - Methadone Anesthesia For Kidney Transplant Receptors Phase 3
Completed NCT05769686 - Laparoscopic Donor Nephrectomy Score, a New Scoring System for Preoperative Prediction of Difficulty of Laparoscopic Donor Nephrectomy
Completed NCT03949036 - Comparison of Two Different Preload Targets of Stroke Volume Variation During Kidney Transplantation N/A
Completed NCT03658876 - Predictors of Response to Iron and Erythropoietin Stimulating Agents Phase 4
Not yet recruiting NCT04377243 - Immunotherapy of Chronic Kidney Failure Phase 2
Active, not recruiting NCT05418816 - SelfWrap-Assisted Arteriovenous Fistulas N/A
Completed NCT06454981 - Clinical Trial for Effectiveness and Safety Evaluation of Hemodiafilter N/A
Active, not recruiting NCT03436368 - Continuous Spinal Anesthesia in Renal Transplantation N/A
Recruiting NCT03778944 - Enhancing Renal Graft Function During Donor Anesthesia N/A
Recruiting NCT05521425 - Randomized Controlled Trial on 3D Printed Assistive Device for Continuous Ambulatory Peritoneal Dialysis N/A
Recruiting NCT05077163 - Patients With Acute Renal Failure During Severe COVID-19
Active, not recruiting NCT05381961 - Observational Study of BIS in Hemodialysis Patients
Completed NCT03781726 - Multi-center Study to Transplant Hepatitis-C Infected Kidneys Phase 4